TheraRadar
Landscape / Endocrine
Data updated: Jun 28, 2026

Acromegaly Clinical Trial Landscape

Acromegaly is being studied across 51 clinical trials registered since 2008, with 9 programs currently active. The competitive pipeline includes 4 active Phase 3 trials, 3 active Phase 2 trials, and 2 active Phase 1 trials.

Top industry sponsors include Crinetics Pharmaceuticals Inc., Marea Therapeutics, Debiopharm International SA.

Trial activity

9 active / 51 total since 2008
Active by phase 4 Ph3 / 17 3 Ph2 / 19 2 Ph1 / 9 0 Ph4 / 6

Sponsor activity

Who is running trials now — green active, blue completed, red failed/terminated.

Sorted by active Active Done Failed
Crinetics Pharmaceuticals Inc. 3 2 0
Marea Therapeutics 2 0 0
Debiopharm International SA 1 0 1
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 1 1 0
AstraZeneca 1 0 0
Triastek (Shanghai) Limited 1 0 0
Ipsen 0 4 3
Novartis 0 5 0
Camurus AB 0 3 0
Ionis Pharmaceuticals, Inc. 0 3 0

All 10 active Acromegaly sponsors

Unlock the remaining 2 sponsors with active / completed / failed counts — sortable and exportable.

Unlock with Pro

How the field has grown

New-trial starts peaked in 2019 (7 registered); 2025 saw 3. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (8 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.

New trials started by year

2016
2
2017
2
2018
2
2019
7
2020
1
2021
3
2022
1
2023
1
2024
1
2025
3
2026
3

TheraRadar.com

Median Phase 3 enrollment by start year

2016 (1)
146
2017 (1)
10
2018 (0)
0
2019 (2)
104
2020 (0)
0
2021 (2)
85
2022 (0)
0
2023 (0)
0
2024 (0)
0
2025 (1)
119
2026 (1)
154

TheraRadar.com

Full trial pipeline

Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.

NCT06930625 RECRUITING
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
Debiopharm International SA n=119
NCT05192382 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
Crinetics Pharmaceuticals Inc. n=111
NCT04837040 ACTIVE NOT RECRUITING
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
Crinetics Pharmaceuticals Inc. n=58
NCT07623824 NOT YET RECRUITING
A Phase III Clinical Trial to Evaluate the Efficacy and Safety of Octreotide Long-acting Injection in Patients With Acromegaly
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. n=154
NCT04125836 COMPLETED
A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
Camurus AB n=135
NCT04076462 COMPLETED
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
Camurus AB n=72
NCT00690898 COMPLETED
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
Ipsen n=108
NCT02685709 COMPLETED
Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
Chiasma, Inc. n=146
NCT02952885 COMPLETED
Strict IGF-1 Control in Acromegaly
Unity Health Toronto n=10
NCT02354508 COMPLETED
Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
Novartis Pharmaceuticals n=123
NCT02493517 COMPLETED
Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
Ipsen n=128
NCT01137682 COMPLETED
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
Novartis Pharmaceuticals n=198
NCT01412424 COMPLETED
Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly
Chiasma, Inc. n=155
NCT00600886 COMPLETED
Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly
Novartis Pharmaceuticals n=358
NCT00765323 TERMINATED
Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly
Endo Pharmaceuticals n=169
NCT01295060 TERMINATED
Long-term Safety and Efficacy Study of Octreotide Implant in Patients With Acromegaly
Endo Pharmaceuticals n=12
NCT00642421 TERMINATED
Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients
Ambrilia Biopharma, Inc. n=40

Full Acromegaly Pipeline

Every trial across Phase 1–4, plus enrollment analytics. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only